FDA Decision Days: How Biotech Catalysts Work and How Investors Track Them

Biotech catalysts like FDA decisions and earnings can move a stock 40% in a single session, which is exactly why they blow up unprepared portfolios. This guide shows you how to track binary events like Belite Bio's FDA priority review and Protalix's earnings beat, size these positions defensively, and set alerts so no catalyst catches you flat-footed.

What is a binary biotech catalyst and why does it matter?

A binary biotech catalyst is a scheduled event, usually an FDA decision or a clinical trial readout, that resolves in one of two directions and causes a large, often permanent, price move. Unlike a normal earnings quarter, the outcome is close to all-or-nothing for the stock.

On August 12, two very different examples landed on the same day. Belite Bio (BLTE) won FDA priority review for its lead candidate, a genuine binary regulatory event. The same day, Protalix BioTherapeutics (PLX) beat both EPS and revenue estimates, a softer earnings catalyst that still moved the stock.

The distinction matters for how these events behave:

• Hard binary events: FDA approval or rejection (PDUFA dates), Phase 3 topline data, advisory committee votes. Outcomes can gap a stock 30 to 70 percent.
• Soft catalysts: quarterly earnings, revenue guidance, partnership news. Moves are usually 5 to 20 percent and less existential.
• Priority review grants: like Belite's, these shorten the FDA timeline to roughly 6 months instead of 10, which pulls the real binary decision date closer.

How do FDA decision dates and PDUFA dates actually work?

An FDA decision date, formally called a PDUFA date (Prescription Drug User Fee Act target date), is the deadline by which the FDA aims to complete its review of a new drug application. This date is the single most important number for anyone holding a clinical-stage biotech.

The timeline you need to track

Once a company files, the FDA sets a PDUFA date, and a priority review designation like Belite Bio's compresses that window. Standard review targets about 10 months; priority review targets roughly 6 months.

• Filing accepted: the clock starts and the PDUFA date is assigned.
• Advisory committee (AdCom): optional, but a rejection recommendation here can crush a stock weeks before the decision.
• PDUFA date: the binary day. Approval, rejection (Complete Response Letter), or delay.

You can verify filing status and review classifications directly on SEC filings, since companies disclose material regulatory updates in 8-Ks.

How do investors think about sizing a binary biotech position?

Position sizing is often described as the entire game with binary biotech, because the outcome distribution is bimodal, not smooth. A rule many experienced catalyst traders describe is not risking more on a single binary event than they can afford to see fully halved overnight.

A sizing framework investors describe

Concentration risk is the danger that a single holding or bucket is large enough to damage a whole portfolio when it moves against you. Some catalyst traders describe capping an aggregate biotech-catalyst bucket and sizing each name inside it. A structure often cited for a diversified retail investor:

• Total speculative biotech bucket: some describe holding it to no more than a 5 to 10 percent share of a portfolio.
• Single binary event: often described as a 1 to 3 percent share of a portfolio per name.
• Assumed downside on a miss: a 40 to 60 percent gap is what many model, not 10 percent.

The math is straightforward to run. If BLTE is a 2 percent share of a book and drops 50 percent on a Complete Response Letter, the total portfolio loss is roughly 1 percent. If it were a 15 percent share of a book, the same event costs roughly 7.5 percent, and that is how accounts blow up.

This same concentration discipline applies beyond biotech. If you already know that 40 percent of a portfolio sitting in tech is a real risk, the tail on speculative biotech is even fatter. Reviewing your own weightings is the first step to seeing where that exposure sits.

How do you set event alerts for FDA decisions and earnings?

Many investors set alerts before taking a position, not after, so the catalyst date is locked in the moment they buy. In PortfolioTrackr you can attach both price alerts and calendar-based event reminders to any holding, which means a PDUFA date and an earnings date live right next to your cost basis.

Which alerts matter most

Not every notification is worth the noise. The alerts that most often change a decision:

• Earnings date alerts: triggered a few days before an earnings print. Protalix's EPS and revenue beat is exactly the kind of event this catches.
• Volatility and gap alerts: a price move of more than 15 percent flags that a catalyst likely resolved.
• Calendar reminders: a manual note for a known PDUFA date or AdCom meeting, since these are not always in standard data feeds.

PortfolioTrackr handles this by letting you tag a position with a custom event date and threshold, so a Belite Bio priority-review decision or a Protalix earnings call pings you without you scanning headlines all day. If you have not linked your accounts yet, start by connecting your brokerage account to the tracker so every catalyst position shows up automatically.

Holding through the catalyst versus trading around it

There is no universally correct answer, and position size tends to shape the choice. When a name is small enough that a full loss is a rounding error on a portfolio, holding through the binary event is something some investors describe as defensible. When it is large, the risk to the whole book is proportionally greater.

Three common playbooks investors describe, ranked by risk:

Remember that biotech gaps are usually not tradeable in the moment. When BLTE or PLX gaps at the open, a stop-loss, which is a standing order to sell once a price is reached, does not protect against an overnight gap because there is no trading between the close and the open. US stocks settle T+1 since May 2024, but that does nothing for an overnight gap. The only real control is the size set the day before.

How do you monitor biotech catalysts across multiple brokers?

Consolidating every position into one view means no catalyst hides in a forgotten account. Many retail investors hold speculative biotech at Alpaca or Interactive Brokers while keeping core holdings at Schwab, and split accounts are exactly how a large binary position goes unmanaged.

Why one dashboard beats broker apps

Broker apps show you a single account and rarely surface PDUFA dates or aggregate your true biotech exposure. A dedicated tracker fixes both problems:

• True bucket exposure: see that a combined biotech bucket is a 9 percent share, not the 3 percent it appeared to be.
• Unified catalyst calendar: every earnings date and event across brokers in one list.
• Cross-asset context: biotech sits alongside your stocks, ETFs, and crypto so risk is measured on the whole book.

If you are weighing tools for this, the portfolio tracker versus spreadsheet comparison explains why manual sheets fall apart the moment you hold volatile positions across three brokers. A spreadsheet will not ping you the morning of a PDUFA date.

What risk-management habits keep catalyst trading sustainable?

Investors who last tend to treat every binary biotech position as a small, pre-sized bet inside a diversified portfolio rather than a core holding. The investors who survive catalyst trading are not the ones who pick every winner; they are the ones who cap the damage from every loser.

Habits investors describe building before an FDA date:

1. Define the bucket first. Some decide the total share of speculative biotech they allow and track it against that limit.
2. Model a 50 percent gap. Many model the worst realistic outcome, not the average one.
3. Set the alert at entry. Attaching the PDUFA or earnings date to the position immediately keeps the date visible.
4. Review after wins. A doubled position is now a larger share of the book, which is why some investors revisit their weightings after a gain.
5. Diversify the correlation. Ten small-cap biotechs still crash together in a sector selloff.

This is the same defensive logic that applies to any concentrated exposure, whether it is a commodity shock or a rate move. The same discipline that helps you track a gold allocation with diversifier alerts applies to a binary biotech position: check the size, set the alert, and let the rules do the work.

The bottom line

Binary biotech catalysts move sharply, and investors who manage them lean on strict position sizing and pre-set alerts. Belite Bio's FDA priority review and Protalix's earnings beat both landed on August 12, and both were foreseeable events that could have been sized and alerted for in advance.

The approach many describe is boring on purpose: a biotech bucket held to a 5 to 10 percent share, single binary positions kept to a 1 to 3 percent share, a 50 percent downside modeled, and PortfolioTrackr surfacing every catalyst date across your brokers so nothing catches you flat-footed. Done that way, one bad FDA decision becomes a small loss instead of a blown-up account.

Find out what you are actually exposed to

Sector and currency concentration across every account you hold, benchmarked against the S&P 500, NASDAQ and gold.

Check My Exposure

See the live demo first →

Frequently asked questions